Oric Pharmaceuticals (ORIC) Common Equity (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Common Equity came in at $415.6 million in Q1 2026, up 89.11% YoY from $219.7 million in Q1 2025, and up 8.12% on a QoQ basis from $384.4 million in Q4 2025.
Oric Pharmaceuticals (ORIC) Common Equity (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of Common Equity data on file, last reported at $415.6 million in Q1 2026.
- Quarterly Common Equity rose 89.11% year-over-year to $415.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $415.6 million (up 89.11% YoY) and the FY2025 annual result came in at $384.4 million, up 58.09% from the prior year.
- Common Equity rose to $415.6 million in Q1 2026, from $384.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $415.6 million in Q1 2026 to a low of $202.8 million in Q1 2023.
- A 5-year average of $280.5 million and a median of $253.1 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity slumped 33.14% — and 2026, when it jumped 89.11%.
- Tracing ORIC's Common Equity over 5 years: stood at $222.4 million in 2022, then rose by 0.78% to $224.1 million in 2023, then rose by 8.49% to $243.1 million in 2024, then jumped by 58.09% to $384.4 million in 2025, then increased by 8.12% to $415.6 million in 2026.
- The last three Common Equity figures came in at $415.6 million (Q1 2026), $384.4 million (Q4 2025), and $406.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | 381.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 381.26 Mn |
| Mar 31, 2026 | 415.56 Mn |
| Dec 31, 2025 | 384.36 Mn |
| Sep 30, 2025 | 406.92 Mn |
| Jun 30, 2025 | 324.00 Mn |
| Mar 31, 2025 | 219.74 Mn |
| Dec 31, 2024 | 243.12 Mn |
| Sep 30, 2024 | 273.99 Mn |
| Jun 30, 2024 | 302.40 Mn |
| Mar 31, 2024 | 328.65 Mn |
| Dec 31, 2023 | 224.09 Mn |
| Sep 30, 2023 | 247.41 Mn |
| Jun 30, 2023 | 268.80 Mn |
| Mar 31, 2023 | 202.81 Mn |
| Dec 31, 2022 | 222.35 Mn |
| Sep 30, 2022 | 214.82 Mn |
| Jun 30, 2022 | 236.87 Mn |
| Mar 31, 2022 | 253.08 Mn |
| Dec 31, 2021 | 272.98 Mn |
| Sep 30, 2021 | 291.54 Mn |